Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.

Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.

Participants received placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.

Cohort A: Placebo

Participants received ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.

Cohort A: ISIS-APO(a)Rx < 2000 mg

Cohort A: ISIS-APO(a)Rx >= 2000 mg

Cohort B: Placebo

Cohort B: ISIS-APO(a)Rx < 2000 mg

Cohort B: ISIS-APO(a)Rx >= 2000 mg

Total

Sex: Female, Male

Race/Ethnicity, Customized

Data are reported for evaluable participants.

Percent Change From Baseline in Lipoprotein Lp(a) Plasma Concentration at Day 85/Day 99

An adverse event is any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product.

Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

Overall Study

Ionis Pharmaceuticals, Inc.

Elevated Lipoprotein(a)

ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.

ISIS-APO(a)Rx

Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.

Placebo

Chicoutimi Hospital

Clinique des Maladies Lipidiques de Quebec Inc.

Herlev University Hospital

Charite - University Hospital Berlin - Campus Virchow - Hospital

Uniklinik Koeln, Zentrum fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP)

Otto-von Guericke Universitaet, Uniklinik Magdeburg

University of Amsterdam - Dept. of Vascular Medicine F4-109

Academic Hospital Maastricht

Sint Franciscus Gasthuis

University Medical Center Utrecht

Heart of England NHS Foundation Trust

Barlow Medical Centre

Newcastle Upon Tyne Hospitals

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)

Parkinson's Disease

25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid

PD vitamin supplementation

Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.

PD exercise intervention

25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.

PD vitamin + exercise

New York Institute of Technology, New York College of Osteopathic Medicine, Academic Health Care Center, Adele Smithers Parkinson's Disease Treatment Center

disulfide/cévní mozková příhoda

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Vitamin B6, B12, Folic Acid and Exercise in Parkinson's Disease

Nejúplnější databáze léčivých bylin podložená vědou